• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics Inc (NQ: DYN )

    34.65 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2
    Open 34.65
    Bid (Size) 31.40 (1)
    Ask (Size) 55.44 (2)
    Prev. Close 34.65
    Today's Range 34.65 - 34.65
    52wk Range 6.400 - 36.60
    Shares Outstanding 58,310,703
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +165.31%
    +165.31%
    1 Month
    +10.32%
    +10.32%
    3 Month
    +24.46%
    +24.46%
    6 Month
    +165.31%
    +165.31%
    1 Year
    +208.82%
    +208.82%

    More News

    Read More
    Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    The 3 Most Undervalued Biotech Stocks to Buy in June 2024
    Via InvestorPlace
    Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Announces Proposed Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Why Is Dyne Therapeutics Stock Soaring On Monday?
    Via Benzinga
    Tech Surge Boosts Nasdaq To Record Highs
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
    Via Investor's Business Daily
    Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Dyne Therapeutics Announces CEO Transition
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.